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Abstract
 
Protective immunity against pathogens such as 
 
Leishmania major
 
 is mediated by interleukin (IL)-12–
dependent Th
 
1
 
-immunity. We have shown previously that skin-dendritic cells (DCs) from
both resistant C57BL/6 and susceptible BALB/c mice release IL-12 when infected with 
 
L. ma-
jor
 
, and infected BALB/c DCs effectively vaccinate against leishmaniasis. To determine if cyto-
kines other than IL-12 might influence disease outcome, we surveyed DCs from both strains
for production of a variety of cytokines. Skin-DCs produced significantly less IL-1
 
 
 
 in re-
sponse to lipopolysaccharide/interferon 
 
 
 
 or 
 
L. major
 
 when expanded from BALB/c as com-
pared with C57BL/6 mice. In addition, IL-1
 
 
 
 mRNA accumulation in lymph nodes of 
 
L. ma-
jor–
 
infected BALB/c mice was 
 
 
 
3-fold lower than that in C57BL/6 mice. Local injections of
IL-1
 
 
 
 during the first 3 d after infection led to dramatic, persistent reductions in lesion sizes. In
 
L. major
 
–infected BALB/c mice, IL-1
 
 
 
 administration resulted in increased Th
 
1
 
- and strikingly
decreased Th
 
2
 
-cytokine production. IL-1
 
 
 
 and IL-12 treatments were similarly effective, and
IL-1
 
 
 
 efficacy was strictly IL-12 dependent. These data indicate that transient local administra-
tion of IL-1
 
 
 
 acts in conjunction with IL-12 to influence Th-development in cutaneous leish-
maniasis and prevents disease progression in susceptible BALB/c mice, perhaps by enhancing
DC-induced Th
 
1
 
-education. Differential production of IL-1 by C57BL/6 and BALB/c mice
may provide a partial explanation for the disparate outcomes of infection in these mouse strains.
Key words: dendritic cell • IL-1 • 
 
Leishmania major
 
 • infection • T helper cell type 1/T helper 
cell type 2 immune response
 
Introduction
 
Leishmania
 
 infections represent a significant health problem
worldwide. Current therapeutic and vaccination strategies
are inadequate. Control of disease and long lasting immu-
nity in humans and mice is associated with Th
 
1
 
-predomi-
nant immunity, whereas development of Th
 
2
 
-responses
leads to progressive disease (for a review, see reference 1).
Recent data suggests that IFN-
 
 
 
 release by CD8
 
 
 
 
 
Leishma-
nia major
 
–specific T cells (Tc
 
1
 
) may also promote the devel-
opment of protective immunity (2, 3).
In cutaneous leishmaniasis, inoculated promastigotes are
rapidly taken up by resident dermal M
 
 
 
. Several laborato-
ries, including our own, have suggested that epidermal
Langerhans cells (LCs)
 
*
 
 or dermal DCs rather than M
 
 
 
, are
responsible for the initiation of anti-parasite immunity in
cutaneous leishmaniasis (4–6). We have suggested that LCs
are ultimately recruited to 
 
L. major
 
 inoculation sites where
they ingest parasites (presumably released from lysed M
 
 
 
,
fibroblasts, or apoptotic neutrophils). This leads to LC/DC
activation (5) and translocation of LC/DC from skin to
draining LN eventuating in T cell priming (7).
 
Address correspondence to Dr. Esther von Stebut, Department of Der-
matology, University of Mainz, Langenbeckstrasse 1, 55131 Mainz,
Germany. Phone: 49-6131-175731; Fax: 49-6131-176614; E-mail:
vonstebu@mail.uni-mainz.de
 
*
 
Abbreviations used in this paper:
 
 BMDC, bone marrow–derived dendritic
cell; FSDDC, fetal skin–derived DC; LC, Langerhans cell.T
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IL-1
 
 
 
 in Cutaneous Leishmaniasis
 
Development of protective Th
 
1
 
-responses requires IL-12
during priming of naive T cells. Although M
 
 
 
 comprise
the major parasite reservoir in vivo, they fail to produce IL-
12 after infection with 
 
Leishmania
 
 (8). In contrast, 
 
L. major
 
–
infected skin DCs do release IL-12 (5). Thus, DCs may be
an important early source of IL-12 and they are likely to be
involved in the initiation of protective immunity. Interest-
ingly, infection of both C57BL/6 and BALB/c LC-like
DCs with 
 
L. major
 
 stimulated IL-12 production and injec-
tion of infected BALB/c LCs or DCs loaded with antigen
into naive susceptible animals induced Th
 
1
 
-immunity that
prevented disease (4, 9).
In the present study, we surveyed DCs from both 
 
Leish-
mania
 
-susceptible and -resistant mice for production of
other cytokines that might influence Th
 
1
 
-differentiation
and the outcome of infection. We found that skin-DCs
from BALB/c mice produced several-fold less IL-1 in re-
sponse to various stimuli than their C57BL/6 counter-
parts. We also determined that treatment of infected mice
with IL-1 during T cell priming enhanced Th
 
1
 
-develop-
ment and attenuated lesion development and disease
progression in both susceptible BALB/c and resistant
C57BL/6 mice. We propose that differences in the pro-
duction of IL-1 by skin-derived DCs in BALB/c and
C57BL/6 mice may influence the outcome of infection in
these mouse strains.
 
Materials and Methods
 
Animals.
 
6 to 8-wk-old BALB/c and C57BL/6 mice were
purchased from the NCI Animal Production Program. BALB/c
mice with targeted mutations of the IL-12 p40 gene (10) were
kindly provided by Dr. E. Schmitt (Institute of Immunology,
University of Mainz, Germany). All animals were housed and
used in experiments in accordance with institutional guidelines.
 
Propagation of Cells and Parasites.
 
Immature LC-like fetal
skin–derived DCs (FSDDCs) were generated as described previ-
ously (5, 11). In brief, fetal skin cells from day 16 mice were cul-
tured in GM-CSF– and M-CSF–supplemented media and, after
 
 
 
2 wk, DC aggregates were isolated. Inflammatory skin-derived
M
 
 
 
 (skin-M
 
 
 
) were elicited by subcutaneous injection of poly-
acrylamide beads and enriched to homogeneity as described (5,
12–14). Bone marrow–derived DCs (BMDCs) were generated
in GM-CSF and IL-4–containing media (15) and harvested as
immature DCs on day 6. Bone marrow–derived M
 
 
 
 and
thioglycollate-elicited peritoneal M
 
 
 
 (P-M
 
 
 
) were generated
for comparison (16).
Metacyclic promastigotes or amastigotes of 
 
L. major
 
 clone VI
(MHOM/IL/80/Friedlin) were prepared as described previously
(5, 13). Isolated parasites were opsonized with 5% BALB/c nor-
mal mouse serum and washed before in vitro infections.
 
Cytokine Analyses.
 
DC and M
 
 
 
 populations were subcul-
tured in their basal media (RPMI 1640/5% FBS with 10 ng/ml
GM-CSF and M-CSF [FSDDC], RPMI/5% FCS with 10 ng/ml
GM-CSF and IL-4 [BMDC] and DMEM/10% FBS [M
 
 
 
], re-
spectively) in 24-well plates at 2 
 
 
 
 10
 
5
 
 cells/ml/well. 
 
L. major
 
amastigotes (3 organisms/cell) or 
 
E. coli
 
 LPS (100 ng/ml; kindly
provided by Dr. Stephanie Vogel, Uniformed Services University
of the Health Sciences, Bethesda, MD), and IFN-
 
 
 
 (1,000 U/ml;
Genzyme) were added as indicated.
Total RNA was isolated from FSDDCs using RNAzol B (Tel-
Test) after incubation for 18 h in the presence or absence of
agonists. Cytokine mRNA was quantitated using a multiprobe
RNase protection assay system (RiboQuant; BD Biosciences) and
template set mCK2. 3 
 
 
 
g of total RNA and 3 
 
 
 
 10
 
5
 
 cpm of the
radiolabeled probe were used per lane. Spontaneous and agonist-
induced cytokine production was measured in DC and M
 
 
 
 su-
pernatants using ELISA kits specific for murine IL-1
 
 
 
 and IL-1
 
 
 
(Endogen). Cell-associated IL-1 was determined as described pre-
viously (11).
Production of IL-1
 
 
 
 mRNA in vivo was quantitated by semi-
quantitative RT-PCR. RNA was extracted from draining lymph
nodes using the RNeasy Kit (QIAGEN) and reverse transcribed
using Stratascript reverse transcriptase (Stratagene). Primers for
murine GAPDH and IL-1
 
 
 
 were designed using Primer Express
software (Applied Biosystems). Sequences were as follows:
GAPDH 5
 
 
 
 CCA TCA ACG ACC CCT TCA TTG ACC, 3
 
 
 
TGG TTC ACA CCC ATC ACA AAC ATG; IL-1
 
 
 
 5
 
 
 
 CAC
CTT ACA CCT ACC AGA GTG ATT TG, 3
 
 
 
 TGT TGC
AGG TCA TTT AAC CAA GTG. PCR amplification was per-
formed with 
 
 
 
150 pg cDNA in 20 
 
 
 
l 1
 
 
 
 reaction buffer with 0.5 U
Taq polymerase (Applied Biosystems), 200 
 
 
 
M dNTP, 0.4 
 
 
 
M of
each primer (5 min 94
 
 
 
C, followed by 20 (GAPDH) or 32 cycles
(IL-1
 
 
 
) of 94
 
 
 
C 15 s, 64
 
 
 
C 25 s, 72
 
 
 
C 20 s, and 7 min at 72
 
 
 
C).
Control reactions were stopped at lower and higher cycle numbers
to document amplification in the linear range of the PCR. PCR
products were resolved by 3% agarose gel electrophoresis and
quantitated using a LumiQuant densitometer (Boehringer). Strain
differences in IL-1
 
 
 
 expression in vivo were confirmed by real
time RT-PCR. PCR amplifications were performed in duplicates
with 5 
 
 
 
l of dilutions (1:40 to 1:640) of the RT-reaction mix us-
ing the QuantiTectTM SYBR
 
®
 
 Green PCR Kit (QIAGEN).
PCR reactions were performed with an ABI Prism
 
®
 
7900 HT Cy-
cler (Applied Biosystems). PCR-results were analyzed using SDS
2.0 software (Applied Biosystems). Relative abundances of IL-1
 
 
 
transcripts were normalized to GAPDH.
 
Infections.
 
Groups of five mice were infected with high dose
(2 
 
 
 
 10
 
5
 
) or low dose (10
 
3
 
) inocula of infectious stage metacyclic
promastigotes (17) by injection of 
 
 
 
10 
 
 
 
l of PBS containing par-
asites into the dorsal dermis of the left ears. For treatment pur-
poses, murine IL-1
 
 
 
, IL-1
 
 
 
, IL-6, IL-12 p70, or IL-18 (all from
R&D Systems) were diluted in serum-free PBS and injected in-
tradermally as indicated in doses between 0.1 and 100 ng/10 
 
 
 
l.
Lesion volumes were measured weekly in 3 dimensions using
a caliper, and are reported (in mm
 
3
 
) as ellipsoids [(a/2
 
 
 
 b/2
 
 
c/2)   4/3    ]. Organisms present in lesional tissue were enu-
merated at the indicated times ( 3 animals/group) using a limit-
ing dilution assay in Schneider’s Drosophila media (BioWhit-
taker), 2% human urine, 10% FCS, 2% glutamine, 1% penicillin/
streptomycin, and 0.5% HEPES as described (17).
For measurement of in vitro cytokine production, retroauricu-
lar LNs were recovered and single-cell suspensions were pre-
pared. In some experiments, CD4  and CD8  T cells were
enriched from LN suspensions by positive selection using anti-
body-coated magnetic beads (Miltenyi Biotec). Cells were added
to 96-well plates without antigen, with BMDCs (APC/T cell ra-
tio: 1:5) and with L. major-lysate (17) (at 106 LN cells or 5   105
T cells/ 200  l) of complete RPMI containing  -mercaptoetha-
nol (5   10 5 M). Culture supernatants were assayed for cytokine
production after 48 h using ELISAs specific for murine IFN- ,
IL-12 p40 (R&D Systems), and IL-4 (BD Biosciences).
Statistics. Statistical analysis was performed using the unpaired
Student’s t test.T
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Results
Skin-derived APCs from Leishmania-susceptible Mice Produce
Less IL-1 . We have previously shown that FSDDC
from both Leishmania-resistant C57BL/6 and susceptible
BALB/c mice release comparable amounts of IL-12 p70
when infected with L. major amastigotes in vitro, and that
infected BALB/c DC can vaccinate against disease (9). To
determine if strain-dependent differences in factors other
than Th1-promoting IL-12 might be responsible for ge-
netic determination of disease outcome, we surveyed DCs
from both strains for production of other cytokines. We
observed up-regulation of mRNA levels for IL-12 p35 and
p40, IL-1 / , IL-1RA as well as MIF in stimulated FS-
DDC compared with untreated control cells (unpublished
data). Quantitation of mRNA expression in three indepen-
dent experiments revealed that LPS/IFN- –stimulated or
L. major–infected FSDDCs from BALB/c mice contained
2.9 and 1.7-fold less IL-1  mRNA (Fig. 1 A), respectively,
whereas no strain differences in expression of IL-12 p40,
IL-1RA, or IL-1  mRNA were found (unpublished data).
Thus, the level of bioactive IL-1, as determined by the ra-
tio of IL-1/IL-1RA, is reduced in activated BALB/c DCs
compared with DCs from C57BL/6 mice.
LPS/IFN- –stimulated or L. major–infected FSDDC
also produced significantly less IL-1  protein (Fig. 1 B)
when isolated from BALB/c rather than C57BL/6 mice
(266   142 vs. 839   217 and 12   3 vs. 41   11 pg/106
cells/ml, P   0.05). Similar to skin-derived FSDDCs, LPS-
stimulated inflammatory skin-M  derived from BALB/c
mice also contained 2.5-fold less IL-1  than skin-M  from
C57BL/6 mice (Fig. 1 B). Previously, L. major was shown
to selectively increase IL-1  mRNA accumulation in M ,
although levels were lower than those induced by LPS
(18). In our hands, L. major–infection of skin-M  did not
induce production of detectable amounts of IL-1 . In con-
trast to skin DCs, standard APC populations from noncuta-
neous sources (BMDC, P-M ) did not exhibit strain-
dependent differences in IL-1  synthesis (Fig. 1 B).
To test the in vivo relevance of our in vitro findings,
we performed additional studies to quantify IL-1  ex-
pression in vivo after L. major infection of BALB/c or
C57BL/6 mouse ear skin (Fig. 1 C). Using semi-quantita-
tive RT-PCR, we determined that IL-1  mRNA levels
in draining LN were  3-fold lower in BALB/c as com-
pared with C57BL/6 mice (e.g., 48 h: 1.9- and 4,3-, 96 h:
2.8- and 3.1-fold difference in two independent experi-
ments). Preinfection controls and earlier time points did
not show striking differences (0.8- to 1.2-fold less IL-1 
RNA in BALB/c compared with C57BL/6 LN). Strain
differences in IL-1  mRNA expression was confirmed
using real time PCR (48 h: 3.2- and 2.3-fold difference
between BALB/c and C57BL/6 LN preparations in two
independent experiments).
Administration of IL-1  During T Cell Priming Improves
Disease Outcome in both Leishmania-susceptible and -resistant
Mice. To determine if skin-DC-derived IL-1  might in-
fluence disease outcome, we injected IL-1  into sites of
standard high dose inoculation (2   105 metacyclic pro-
mastigotes; Fig. 2, A and B). In both BALB/c and C57BL/
6 mice, administration of IL-1  during the first 3 d dramat-
ically reduced ear lesion volumes when followed over the
course of 3 mo. BALB/c mice treated with 50 ng IL-1  on
days 1–3 after infection were protected from progressive
disease for more than 12 wk, whereas PBS-treated controls
had to be killed after 6 weeks due to uncontrolled lesion
Figure 1. Langerhans cell-like dendritic cells of Leishmania-susceptible
BALB/c mice produce less IL-1  than dendritic cells of resistant C57BL/
6 mice. (A) FSDDCs were stimulated with LPS/IFN-  (100 ng/1,000
U/ml) or L. major amastigotes (3:1 organisms/cell) for 18 h and expres-
sion of various cytokines was determined using RNase protection assays.
Relative intensities of bands corresponding to IL-1  mRNA and mean
fold differences between C57BL/6 and BALB/c DC of three indepen-
dent experiments are shown. (B) FSDDCs (n   5), BMDCs (n   6),
peritoneal M  (P-M , n   5), and skin-M  (n   4) were stimulated as
indicated. After 18 h, protein levels in cell lysates were determined by
ELISA (ng/ 106 cells, mean   SEM). *P   0.05 compared with untreated
control, differences between mouse strains are marked with bars above
columns (**P   0.05). (C) IL-1  mRNA accumulation in lymph nodes of
uninfected mice or, in a separate experiment, mice infected with 2   105
L. major was assessed by semi-quantitative RT-PCR at the time points in-
dicated. Results shown are representative of two independent experiments.T
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194 IL-1  in Cutaneous Leishmaniasis
evolution with tissue ulcerations (Fig. 2 A). Daily treatment
of Leishmania-susceptible BALB/c mice with IL-1  for up
to 2 wk after parasite inoculation did not additionally im-
prove disease outcome (unpublished data). Lesion develop-
ment in Leishmania-resistant C57BL/6 mice was also signif-
icantly attenuated by treatment with IL-1  (Fig. 2 B).
Subsequent studies showed that doses of 100 ng and 10
ng IL-1  administered on days 1–3 after infection were
similarly efficient in reducing skin lesion sizes (Fig. 2 C). In
contrast, 1 ng of IL-1  was not effective. Lesional parasite
loads were also reduced upon treatment with IL-1  (Fig. 2
D). Specifically, 100 ng and 10 ng of IL-1  reduced para-
site burdens of infected ear skin by  2 logs (P   0.005),
whereas 1 ng did not facilitate parasite control in vivo.
The Protective Effect of IL-1  in Cutaneous Leishmaniasis
Does Not Require Local Administration. Because local ad-
ministration of IL-1  into skin is known to activate and
mobilize LCs which may then acquire antigen and migrate
to draining LNs (19), we sought to determine if local ad-
ministration was required for the beneficial effect of IL-1 
in cutaneous leishmaniasis. BALB/c mice were infected in
one ear with high dose inoculae and treated with IL-1  in-
tradermally into infected ears, opposite ears, or into the ret-
roauricular skin of the infected ears (Fig. 2 E). Injection of
IL-1  into skin sites other than the lesional tissue was as ef-
ficacious as local administration. IL-1  injection resulted in
a 32   5% decrease in LC density in epidermal sheets from
injected, but not from contralateral ears (unpublished data).
This suggests that IL-1  does not act by mobilizing LCs in
lesional tissue.
IL-1  Also Protects Against Progressive Disease in Low Dose
Leishmania Infections. We also assessed the efficacy of IL-
1  in infections with low dose inocula (103 infectious-stage
parasites) administered intradermally (17). This experimen-
tal model is more physiologically relevant in that it more
closely mimics natural parasite transmission by sand flies. In
this setting, IL-1  treatment was only successful if adminis-
tered for the initial 14 d after infection (unpublished data)
or between days 11 and 14 after infection (Fig. 2 F). The
original treatment protocol (days 1–3 after inoculation
only) was without effect (unpublished data). This data sug-
gested that IL-1  treatment was only efficacious when
given coincident with the onset of T cell priming which is
delayed in low dose infections (17).
Enhanced Th1-development in IL-1 –treated Leishmania-
infected BALB/c Mice. L. major specific Th1-cells are nec-
essary for efficient elimination of Leishmania parasites from
infected hosts (1). To determine if IL-1  facilitated Th1-
development we assessed antigen-dependent cytokine
production by lesion-draining LN cells from 1 and 3 wk
Leishmania-infected BALB/c mice (Fig. 3 A). As described
previously, LN cells from untreated or PBS-treated BALB/c
mice infected with Leishmania promastigotes produced
large amounts of IL-4 upon stimulation with Leishmania ly-
sate (1). In contrast, LN cells of IL-1 -treated BALB/c
mice showed significantly reduced IL-4 release 1 wk after
infection. IFN-  production was also  2-fold higher in
IL-1 -treated mice than in PBS-treated controls at early
time points. Thus, the ratio between Th/Tc1- and Th/
Tc2-cytokines was significantly skewed toward a Th1-pre-
dominant immune response in IL-1 -treated Leishmania-
infected mice (Fig. 3 A). This effect was still detectable af-
ter 3 wk, although treatment with IL-1  was only given on
days 1, 2, and 3 after infection.
Figure 2. Improvement of disease outcome in Leishmania-susceptible
and -resistant mice after systemic treatment with IL-1 . Groups of  5
BALB/c (A) or C57BL/6 (B) mice were infected with 2   105 L. major
and treated locally with 50 ng IL-1  or PBS on days 1, 2, and 3 after in-
fection. Lesion development was assessed weekly (mean   SEM). Results
are representative of  3 experiments. (C and D) BALB/c mice were in-
fected as described above and treated with different doses of IL-1  as in-
dicated. Lesion volumes were measured after 3 wk and the number of
parasites/lesion was determined in limiting dilution assays. Dots represent
number of parasites in one ear, bars show the arithmetic mean of all mice/
group. (E) Groups of three BALB/c mice were infected with L. major
promastigotes and treated with 50 ng IL-1  or PBS on days 1–3 after in-
fection. Treatment was delivered locally, into the contralateral ear or in-
tradermally into the retroauricular region of the infected side (local LN).
3 wk later, lesion sizes were assessed (mean   SEM). (F) IL-1  treatment
prevents progressive disease in low dose cutaneous leishmaniasis. Groups
of  5 BALB/c mice were infected with 1,000 L. major promastigotes and
treated locally with 50 ng IL-1  or PBS on days 11–14 after infection.
Development of lesions was expressed as mean   SEM. (A–F) Statistical
differences between treatment groups at different time points are indi-
cated as *P   0.05, **P   0.005, and ***P   0.002 compared with PBS-
treated control mice.T
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We next assessed T cell responses in IL-1 -treated
BALB/c mice in more detail (Fig. 3 B). CD4  and CD8 
T cells were isolated from IL-1 - or PBS-treated BALB/c
mice 1 wk after infection and restimulated in vitro with an-
tigen in the presence of APCs. CD8  T cells did not re-
lease IL-4 (or IFN- ) confirming previous results demon-
strating that the source of IL-4 early in infections of BALB/c
mice is CD4  T cells (20). Those studies also indicated
that the specific inability of BALB/c mice to down-regu-
late early IL-4 release contributed to genetic susceptibility
in leishmaniasis. In IL-1 –treated mice, release of IL-4 by
CD4 T cells was dramatically reduced, whereas IFN-  lev-
els were up-regulated. Here, the ratio between IFN-  and
IL-4 in LN cultures was altered from 0.9 in PBS-treated
mice to 8.5 after IL-1  treatment. This data strongly sug-
gests that IL-1  treatment is effective via alteration of
Leishmania-specific CD4  T cell responses.
In subsequent experiments, CD4  T cells were depleted
from BALB/c mice within the first week of infection dur-
ing IL-1  treatment (unpublished data). In accordance
with previous studies (21), BALB/c mice depleted of IL-4–
releasing CD4  T cells had smaller lesion volumes and de-
creased parasite burdens. As expected, IL-1  treatment of
CD4-depleted mice was without additional benefit with
respect to disease outcome.
IL-1  Treatment Is as Effective as Administration of IL-
12. The dominant role of IL-12 in development of pro-
tective immune responses against intracellular pathogens is
well established (1). As we observed strain-dependent vari-
ations in the expression of IL-1  but not IL-12 by DC (9;
Fig. 1 A), we tested the potency and specificity of IL-1  in
leishmaniasis by comparing the effect of local administra-
tion of similar amounts of IL-12, IL-1 , IL-1 , IL-18, and
IL-6 on the course of infection with L. major (Fig. 4).
BALB/c mice were infected with 2   105 promastigotes
and recombinant cytokines were administered locally on
days 1–3 after infection. As expected, mice treated tran-
siently with IL-12 showed reduced lesion sizes after 3 wk
as well as significantly reduced parasite burdens in lesional
tissue. IL-1 , IL-1 , and IL-12 decreased lesion sizes and
Figure 3. IL-1  treatment of Leishmania-susceptible BALB/c results in
Th1-predominant immune responses. BALB/c mice were treated with 50
ng IL-1  or PBS on days 1–3 after infection with 2   105 L. major. (A)
After 1 and 3 wk, LN cells of groups of three mice were harvested and
plated at 106 cells/200  l. Cells were stimulated with soluble Leishmania
antigen (SLA) for 48 h and antigen-specific cytokine release was deter-
mined using ELISAs specific for murine IFN-  and IL-4 (mean   SEM).
For each mouse, the ratio between IFN-  and IL-4 was calculated (see
boxes) and statistical significance was determined (*P   0.05 compared
with PBS-treated controls). (B) After 1 wk, LN cells were isolated and T
cell populations isolated using magnetic beads. Total LN cells (106) or
CD4  and CD8  T cells (5   105) were plated into 96-well plates (200
 l) and BMDCs and SLA added. Cytokine responses were studied after
48 h as described above. One out of two experiments with similar results
is shown.
Figure 4. IL-1  is as efficient as IL-12 for treatment of cutaneous leish-
maniasis in susceptible BALB/c mice. BALB/c mice (five/group) were
inoculated intradermally in the ears with 2   105 metacyclic L. major pro-
mastigotes. Fifty ng of IL-12, IL-1 , IL-1 , IL-18, or IL-6 was injected
locally on days 1–3. After 3 wk, lesion volumes were determined (A) and
expressed as mean   SEM. Organisms were cultured from challenge sites
and enumerated as described (B). Each data point represents the number
of organisms from one ear, bars indicate arithmetic means. Cytokine pro-
files of LN cells were determined by in vitro restimulation with soluble
Leishmania antigen (SLA). Supernatants were assayed for the presence of
IFN-  (C) and IL-4 (D) after 48 h (mean   SEM, boxes represent IFN- /
IL-4 ratios, *P   0.05 compared with PBS-treated controls). Data of one
experiment out of three with similar results is shown.T
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reduced parasite burdens to similar extents (Fig. 4, A and
B). Importantly, both IL-12 and IL-1  increased the pro-
duction of antigen-specific IFN-  in LNs and decreased
IL-4 levels (Fig. 4, C and D). In contrast, administration of
IL-18 was less effective. Although we observed reduced le-
sion volumes and parasite loads, the differences between
IL-18– and PBS-treated mice did not reach statistical sig-
nificance. Treatment with IL-6 during the first 3 d of in-
fection was ineffective.
The Action of IL-1  Is IL-12 Dependent. We also sought
to determine if IL-1  treatment altered IL-12 levels in
draining LN cells and thus contributed to Th1-predomi-
nant differentiation. Infected BALB/c mice were treated
with IL-1  and LN cells were harvested on days 7 and 21
after infection (unpublished data). In all samples examined,
we found slightly increased ( 30%) levels of IL-12 p40
in cultures of LN cells from mice that were treated with
IL-1  compared with PBS-treated control animals. How-
ever, these differences did not reach statistical significance.
As our data suggested that the effects of IL-1  are similar
to those of IL-12 in leishmaniasis, we assessed the outcome
of IL-1  treatment in mice that were deficient in IL-12
p40 (Fig. 5). Wild-type or IL-12 p40-deficient BALB/c
mice were infected with 2   105 promastigotes and treated
with IL-1  as described before. Lesion sizes as well as para-
site burdens in BALB/c IL-12 p40 null mice were higher
when compared with those in control animals, and treat-
ment with IL-1  did not have an effect on disease progres-
sion (Fig. 5, A and B). As expected, we observed virtually
no induction of antigen-specific IFN-  release in IL-12
p40-deficient mice, whereas IL-4 levels were almost un-
changed compared with control mice (Fig. 5, C and D).
Perhaps not surprisingly, IL-1  was not able to induce
Th1-differentiation in IL-12–deficient mice. The lack of
effect of IL-1  on the production of IL-4 in IL-12 p40-
deficient mice indicated that the IL-1 –mediated suppres-
sion of IL-4 was also dependent on the presence of IL-12.
Discussion
Susceptibility of BALB/c mice to cutaneous leishmania-
sis is characterized by an inability to mount efficient anti-
Leishmania  Th1-immunity. DCs facilitate Th-priming in
vivo by producing cytokines such as IL-12 and IFN- .
Thus, susceptibility to infectious diseases could be influ-
enced at the level of tissue DCs, and strain-dependent dif-
ferences in Th1-promoting cytokine production by DCs
might contribute to the L. major susceptibility of BALB/c
mice in leishmaniasis (22). We have previously reported
that L. major susceptibility does not appear to reflect a fail-
ure of BALB/c skin DCs to internalize or to be activated
by parasites, or by the inability of BALB/c T cells to mount
a Th1-response to DC-associated Leishmania antigens (9).
We now report that, in contrast to our observations regard-
ing IL-12 release, BALB/c DCs produce less IL-1  in re-
sponse to stimulation than C57BL/6 DCs. We suggest that
differences in the production of IL-1  in LN in vivo might
influence the outcome of infection in these mouse strains.
The events that shape development of Th1- or Th2-pre-
dominant immunity occur during the initial phase of T cell
priming. Production of cytokines (e.g., IL-12 and IL-4)
that direct the subsequent development of characteristic
Th-subsets are particularly relevant. Several mechanisms
have been shown to contribute to L. major susceptibility of
BALB/c mice (for a review, see reference 23). These in-
clude a lack of parasite containment in early lesions and
higher antigen loads (24), a relative lack of IL-12 release to-
gether with increased production of IL-4 very early after
infection (1), and IL-4–mediated down-regulation of the
IL-12R 2 on Th2-cells (25, 26). In addition, IFN- ,
which could up-regulate IL-12R 2 expression and coun-
teract the inhibitory effect of IL-4, is known to be pro-
duced at lower levels in L. major–infected BALB/c mice as
compared with resistant animals (1).
In this study, treatment with IL-1  during T cell prim-
ing induced Th1-development that attenuated disease pro-
gression in susceptible BALB/c mice. We demonstrated
that this effect was dependent on, and in the regimen em-
ployed as effective as, IL-12. Continuous administration of
IL-12 protein has previously been used together with Leish-
Figure 5. Effective treatment of cutaneous leishmaniasis in Leishmania-
susceptible BALB/c mice with IL-1  requires IL-12. BALB/c or IL-12p40
ko BALB/c mice were infected with high dose inocula into ear skin.
IL-1  or PBS was applied locally on days 1–3 after infection. Three
weeks later, lesions sizes (A) and parasite burdens in lesional ear skin (B)
were determined. Cytokine profiles of lymph node cells restimulated
with antigen were assayed as described in Materials and Methods using
ELISAs specific for IFN-  (C) and IL-4 (D). All data are expressed as
mean    SEM (*P    0.05,  ***P    0.002) and the results shown are
pooled from two experiments (six mice/group).T
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mania antigen as an effective vaccine (27, 28; for reviews,
see references 29 and 23). In IL-1 –treated BALB/c mice,
we found slightly increased amounts of IL-12 in draining
LNs suggesting that IL-1 -mediated up-regulation of IL-
12 production could contribute to Th1-development.
However, no obvious deficiency in IL-12 production by
DCs (the principal source of IL-12 in vivo) in BALB/c
mice has been demonstrated (9) and BALB/c mice express-
ing a transgenic IL-12R 2 exhibited a nonhealing pheno-
type to L. major infection despite maintenance of intact IL-
12 signaling (30). Both studies suggest that factors other
than IL-12 are relevant for development and maintenance
of Th1-responses in BALB/c mice.
Although IL-12 is required for IL-1 efficacy in this
model, IL-1  may have effects on Th1-priming that are not
directly mediated via IL-12. The importance of IL-1 in in-
nate immune responses is well recognized (for a review, see
reference 31), but its role in Th-differentiation is more
controversial. IL-1 was originally reported to promote pro-
liferation of Th2 clones (32). However, Shibuya et al. sub-
sequently demonstrated that IL-1  (and TNF- ) are re-
quired for maximal IL-12-driven Th1-development in
BALB/c, but not C57BL/6, T cells (33). In addition, re-
cent studies indicate that IL-12 can synergize with IL-1 
(or IL-18) for IFN-  production by human T cells (34). Fi-
nally, in the absence of MyD88-signaling, mice immunized
with soluble Toxoplasma-antigen (STAg) failed to develop
detectable Th1-responses despite normal IL-12 release, sug-
gesting that MyD88-dependent signals (e.g., IL-1, IL-18,
and TLR) might also be critical for successful Th1-polariza-
tion (35).
We also tested IL-6 and IL-18 as potential anti-Leishma-
nia treatments. Administration of IL-6 during T cell prim-
ing was without effect, confirming previous results using
knockout mice (36). Although IL-18 and IL-1 are homol-
ogous, act via related receptors (IL-1R), and IL-18 is
known to be involved in Th1-development (for a review,
see reference 37), IL-18 protein was not as effective as IL-
1 /  in reducing lesion development and parasite burdens
in infected mice (38–40). However, IL-18 (like IL-1 ) is
known to potentiate IL-12–driven Th1 development of T
cells from BALB/c mice (for a review, see reference 41). In
the absence of sufficient amounts of IL-1  during T cell
priming, IL-18 and IL-12 responsiveness by BALB/c
CD4  T cells might not be optimal and IL-4–driven Th2-
development may be favored.
Previously, Hunter et al. demonstrated that IL-1  (but
not IL-1 ) prolonged survival of SCID mice after infection
with T. gondii by inducing IFN-  release from NK cells
(42). In addition, a minor role for IL-1 in the control of
parasite growth in leishmaniasis was previously noted in
studies of C57BL/6 IL-1RI-deficient mice. Although le-
sion sizes were similar in IL-1RI knockout- and wild type-
mice, parasite-specific IL-4 production in knockout ani-
mals was increased and lesional tissue contained increased
numbers of parasites (43). In light of the observations by
Shibuya et al. (33), a more dramatic phenotype of IL-1RI
null mice on a Leishmania-resistant background cannot be
expected. It has also previously been reported that delayed
treatment of Leishmania-lesions with anti–IL-1RI mAb or
recombinant IL-1 either did not alter disease outcome or
exacerbated disease (44, 45). These findings are also not in-
consistent with our results, as we observed that IL-1 was ef-
fective only when it was administered early in infections in
the high dose model, or at the time of initial lesion devel-
opment in the low dose setting. Our results confirm and
extend these findings and highlight the role of IL-1 /  as
critical mediators for successful Th1-development against
an infectious organism in vivo.
IL-1 has recently been shown to contribute to the
pathogenesis of several Th1-driven inflammatory and infec-
tious diseases including arthritis and tuberculosis (46, 47). A
previous report suggested that alterations in IL-1 and IL-
1RA levels due to gene polymorphisms contributed to dis-
ease development (47). Specifically, IL-1RA knockout
mice on the BALB/c (but not C57BL/6) background ex-
hibited increased IL-1 bioactivity and spontaneously devel-
oped chronic inflammatory polyarthropathy (48). These
findings are consistent with our findings in cutaneous leish-
maniasis and highlight the role that IL-1 might play as a ge-
netic determinant of both infectious and autoimmune dis-
ease outcome.
In summary, the present study documents an important
role for IL-1 in the regulation of Th1-development and dis-
ease progression in cutaneous leishmaniasis in mice. Future
studies will be directed toward additionally defining the
role of DC-derived IL-1 in T cell priming and characteriz-
ing the alterations in the inflammatory cell infiltrates in-
duced by IL-1. In conjunction with studies designed to
identify key signaling components, we hope to develop a
better understanding of the exact mechanism by which IL-1
regulates Th-differentiation in this important model of a
human disease.
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